Best Penny Stocks Under $1.00 Right Now → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles. Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - Integra ResourcesNYSEAMERICAN:ITRGStock Price: $0.85 (+$0.02)P/E Ratio: -1.57Market Cap: $74.91 millionAverage Trading Volume: 134,980 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.75 (342.8% Upside)Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Gossamer BioNASDAQ:GOSSStock Price: $0.77 (+$0.02)P/E Ratio: -0.55Market Cap: $172.75 millionAverage Trading Volume: 1.17 million sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.65 (899.0% Upside)Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.#3 - Cara TherapeuticsNASDAQ:CARAStock Price: $0.71 (-$0.02)P/E Ratio: -0.33Market Cap: $38.90 millionAverage Trading Volume: 651,617 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.75 (1,270.0% Upside)Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.#4 - Eos Energy EnterprisesNASDAQ:EOSEStock Price: $0.81 (+$0.04)P/E Ratio: -0.38Market Cap: $163.84 millionAverage Trading Volume: 5.28 million sharesConsensus Rating: Moderate Buy (6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.08 (652.4% Upside)Eos Energy Enterprises, Inc. designs, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial and industrial (C&I) applications in the United States. The company offers Znyth technology battery energy storage system (BESS), which provides the operating flexibility to manage increased grid complexity and price volatility. Its flagship product is Gen 2.3 battery module. In addition, the company offers Z3 battery module that provides utilities, independent power producers, renewables developers, and C&I customers with an alternative to lithium-ion and lead-acid monopolar batteries for critical 3- to 12-hour discharge duration applications; battery management system, which provides a remote asset monitoring capability and service to track the performance and health of BESS and identify future system performance issues through predictive analytics; and project management and commissioning services, as well as long-term maintenance plans. Eos Energy Enterprises, Inc. is headquartered in Edison, New Jersey.#5 - KORE GroupNYSE:KOREStock Price: $0.80 (+$0.02)P/E Ratio: -0.42Market Cap: $66.75 millionAverage Trading Volume: 121,094 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.94 (266.4% Upside)KORE Group Holdings, Inc. provides Internet of Things (IoT) services and solutions worldwide. It offers connectivity and location-based services, device solutions, and managed and professional services that are used in the development and support of IoT technology and applications for the Machine-to-Machine market. The company's products include IoT connectivity-as-a-service; connectivity enablement-as-a-service; device management services; and security location based services. It serves customers in healthcare, fleet and vehicle management, asset management, communication services, and industrial/manufacturing sectors. The company was founded in 2002 and is headquartered in Atlanta, Georgia.#6 - DURECTNASDAQ:DRRXStock Price: $0.83 (+$0.02)P/E Ratio: -0.68Market Cap: $25.73 millionAverage Trading Volume: 188,501 sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $27.50 (3,217.6% Upside)DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.#7 - Oatly GroupNASDAQ:OTLYStock Price: $0.97 (+$0.02)P/E Ratio: -1.14Market Cap: $575.30 millionAverage Trading Volume: 1.85 million sharesConsensus Rating: Hold (5 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $2.11 (118.7% Upside)Oatly Group AB, an oatmilk company, provides a range of plant-based dairy products made from oats in Europe, the Middle East, Africa, the Americas, and Asia. It offers Barista edition oatmilk, oatgurts, frozen desserts, ice-creams, and yogurts; cooking products, including cooking cream, in regular and organic, Crème Fraiche, whipping cream, vanilla custard, and spreads in a variety of flavors; and ready-to-go drinks. The company was formerly known as Havre Global AB and changed its name to Oatly Group AB in March 2021. Oatly Group AB was founded in 1994 and is headquartered in Malmö, Sweden.#8 - FTC SolarNASDAQ:FTCIStock Price: $0.42 (+$0.03)P/E Ratio: -0.98Market Cap: $52.50 millionAverage Trading Volume: 708,164 sharesConsensus Rating: Hold (2 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.49 (255.2% Upside)FTC Solar, Inc. engages in the provision of solar tracker systems, software, and engineering services in the United States, Asia, Europe, the Middle East, North Africa, South Africa, and Australia. The company offers a self-powered, two-panel in-portrait, and single-axis tracker solution under the Voyager brand name; and a one module-in-portrait solar tracker solution under the Pioneer brand name. Its customers include project developers and solar asset owners, as well as engineering, procurement, and construction contractors that design and build solar energy projects. The company was incorporated in 2017 and is headquartered in Austin, Texas.#9 - Chicken Soup for the Soul EntertainmentNASDAQ:CSSEStock Price: $0.14 (+$0.00)P/E Ratio: -0.01Market Cap: $4.67 millionAverage Trading Volume: 193,690 sharesConsensus Rating: Hold (2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.00 (2,660.5% Upside)Chicken Soup for the Soul Entertainment, Inc. operates as a streaming video-on-demand (VOD) company in the United States and internationally. It owns and operates various ad-supported and subscription-based VOD networks, including Crackle, Chicken Soup for the Soul, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Popcornflix Comedy, Españolflix, and FrightPix. The company distributes and exhibits content through the Crackle Plus and Redbox streaming services including AVOD, FAST, TVOD platforms, such as connected TVs, smartphones, tablets, gaming consoles, and the web through its owned and operated platforms. It also produces and licenses movies, television series, and programs; and produces long and short-form video content. Chicken Soup for the Soul Entertainment, Inc. was founded in 2014 and is headquartered in Cos Cob, Connecticut. Chicken Soup for the Soul Entertainment, Inc. operates as a subsidiary of Chicken Soup for the Soul Productions, LLC.#10 - Li-CycleNYSE:LICYStock Price: $0.73 (+$0.00)P/E Ratio: -0.94Market Cap: $130.25 millionAverage Trading Volume: 7.54 million sharesConsensus Rating: Hold (2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.25 (621.8% Upside)Li-Cycle Holdings Corp. engages in the lithium-ion battery resource recovery and lithium-ion battery recycling business in North America. The company offers a mix of cathode and anode battery materials, including lithium, nickel, and cobalt, as well as graphite, copper, and aluminum; and copper and aluminum metals. It also provides hub products, such as lithium carbonate, cobalt sulphate, nickel sulphate, and manganese carbonate. Li-Cycle Holdings Corp. is headquartered in Toronto, Canada.#11 - Zevia PBCNYSE:ZVIAStock Price: $0.87 (-$0.03)P/E Ratio: -2.07Market Cap: $62.44 millionAverage Trading Volume: 151,403 sharesConsensus Rating: Hold (2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.17 (379.5% Upside)Zevia PBC, a beverage company, develops, markets, sells, and distributes various carbonated beverages in the United States and Canada. It offers soda, energy drinks, organic tea, and kidz drinks. The company offers its products through a network of food, drug, warehouse club, mass, natural, convenience, and e-commerce channels, as well as grocery distributors and natural product stores and specialty outlets. It provides its products under the Zevia brand name. The company was founded in 2007 and is headquartered in Encino, California.A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.#12 - Americas SilverNYSEAMERICAN:USASStock Price: $0.27 (+$0.01)P/E Ratio: -1.71Market Cap: $68.81 millionAverage Trading Volume: 1.20 million sharesConsensus Rating: Hold (2 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $2.07 (654.0% Upside)Americas Gold and Silver Corporation engages in the acquisition, evaluation, exploration, development, and operation of mineral properties. The company explores for silver, lead, zinc and copper. It principally owns 100% interests in the Cosalá Operations consisting of 67 mining concessions that cover approximately 19,385 hectares located in the state of Sinaloa, Mexico; and Galena Complex situated near the town of Wallace in the state of Idaho, the United States. The company was formerly known as Americas Silver Corporation and changed its name to Americas Gold and Silver Corporation in September 2019. Americas Gold and Silver Corporation was incorporated in 1998 and is headquartered in Toronto, Canada.#13 - Sangamo TherapeuticsNASDAQ:SGMOStock Price: $0.55 (+$0.04)P/E Ratio: -0.38Market Cap: $99.08 millionAverage Trading Volume: 2.20 million sharesConsensus Rating: Hold (3 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $4.93 (789.3% Upside)Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.#14 - Spruce BiosciencesNASDAQ:SPRBStock Price: $0.71 (+$0.02)P/E Ratio: -0.57Market Cap: $29.22 millionAverage Trading Volume: 1.12 million sharesConsensus Rating: Hold (2 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.67 (698.1% Upside)Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.#15 - GalectoNASDAQ:GLTOStock Price: $0.70 (+$0.02)P/E Ratio: -0.48Market Cap: $18.99 millionAverage Trading Volume: 229,847 sharesConsensus Rating: Hold (1 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.33 (661.4% Upside)Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.#16 - Lion ElectricNYSE:LEVStock Price: $0.95 (+$0.00)P/E Ratio: -2.07Market Cap: $215.84 millionAverage Trading Volume: 516,356 sharesConsensus Rating: Hold (1 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $22.12 (2,218.1% Upside)The Lion Electric Company designs, develops, manufactures, and distributes purpose-built all-electric medium and heavy-duty urban vehicles in North America. The company's products include battery systems, chassis, bus bodies, and truck cabins. It distributes truck and bus parts, as well as accessories. The company was incorporated in 2008 and is based in Saint-Jérôme, Canada.A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.#17 - 2UNASDAQ:TWOUStock Price: $0.25 (-$0.00)P/E Ratio: -0.06Market Cap: $20.53 millionAverage Trading Volume: 2.55 million sharesConsensus Rating: Hold (1 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.31 (1,656.1% Upside)2U, Inc. operates as an online education platform company in the United States and internationally. The company operates through two segments, Degree Program and Alternative Credential. The Degree Program segment provides the technology and services to nonprofit colleges and universities to enable the online delivery of degree programs. This segment targets students seeking an undergraduate or graduate degree. The Alternative Credential segment offers online open courses, executive education programs, technical, skills-based boot camps, and micro-credential programs through nonprofit colleges and universities, and other organizations. This segment targets students seeking to reskill or upskill for career or personal development through shorter duration and lower-priced offerings. It provides a platform that provides technology and technology-enabled services; and edX.org, a marketplace that allows to access various catalog of online offerings, which include free offerings and graduate degrees. The company was formerly known as 2Tor Inc. and changed its name to 2U, Inc. in October 2012. 2U, Inc. was incorporated in 2008 and is headquartered in Lanham, Maryland.#18 - LivePersonNASDAQ:LPSNStock Price: $0.47 (+$0.01)P/E Ratio: -0.37Market Cap: $41.84 millionAverage Trading Volume: 2.77 million sharesConsensus Rating: Hold (1 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $3.08 (549.3% Upside)LivePerson, Inc. engages in conversational artificial intelligence. It enables brands to leverage the Conversational Cloud's intelligence engine to connect with consumers through an integrated suite of mobile and online business messaging technologies. The company offers the Conversational Cloud, an enterprise-class digital customer conversation platform, which enables businesses and consumers to connect through conversational channels, such as voice, in-app, and mobile messaging. It also provides professional services; LivePerson's Conversational AI, including conversation builder, manager, and intelligence, and intent manager. In addition, it provides Voice AI, conversational intelligence and insights, and integration services. The company sells its products to Fortune 500 companies, Internet businesses, online merchants, automotive dealers, educational institution, public sector, and not-for-profit organizations. It operates in the United States, Canada, Latin America, South America, Europe, the Middle East, Africa, the United Kingdom, and the Asia-Pacific. LivePerson, Inc. was incorporated in 1995 and is headquartered in New York, New York.#19 - Atara BiotherapeuticsNASDAQ:ATRAStock Price: $0.70 (+$0.00)P/E Ratio: -0.27Market Cap: $83.71 millionAverage Trading Volume: 2.71 million sharesConsensus Rating: Hold (0 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $28.00 (3,892.6% Upside)Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.#20 - Ginkgo BioworksNYSE:DNAStock Price: $0.89 (+$0.05)P/E Ratio: -1.90Market Cap: $1.92 billionAverage Trading Volume: 23.87 million sharesConsensus Rating: Hold (1 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $2.20 (146.9% Upside)Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.#21 - AlloVirNASDAQ:ALVRStock Price: $0.78 (+$0.02)P/E Ratio: -0.42Market Cap: $89.61 millionAverage Trading Volume: 1.18 million sharesConsensus Rating: Reduce (1 Buy Ratings, 3 Hold Ratings, 2 Sell Ratings)Consensus Price Target: $18.67 (2,293.2% Upside)Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.#22 - Viaplay Group AB (publ)OTCMKTS:NENTFStock Price: $0.29Average Trading Volume: 17,750 sharesConsensus Rating: Reduce (0 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)Consensus Price Target: N/AViaplay Group AB (publ) operates as an entertainment provider company in Sweden, rest of Nordics, rest of Europe, and internationally. The company operates Viaplay, an online video streaming service, which offers live sports, original series, films, documentaries, and international TV releases, as well as all-time classic series, and children's animation and series; V sport, series & film, a family of premium-TV channels that offers television entertainment; and Viaplay studios that consists of production companies, which produce scripted content. It also operates TV3, commercial TV channel; TV6, a young male skewed channel; TV8, a channel that provides procedural drama; TV10, a channel for sporting events and documentaries; V4 and TV3+ for young male audiences; TV3 PULS that offers procedural series, cooking, and lifestyle shows; TV3 Sport for sports lovers; and TV3 MAX, which shows comedy and drama series. In addition, it operates radio stations, comprising of Rix FM, Star FM, Bandit Rock, Lugna Favoriter, P4 Lyden av Norge, P5 Hits, P6 Rock, P7 Klem, P8 Pop, P9 Retro, and P10 Country; NRJ, an online TV channel; Bandit, an online station; and I LIKE RADIO, an online music service. Further, the company offers advertising services on TV channels, radio stations, and streaming services. The company was formerly known as Nordic Entertainment Group AB (publ) and changed its name to Viaplay Group AB (publ) in May 2022. Viaplay Group AB (publ) was incorporated in 2017 and is headquartered in Stockholm, Sweden.#23 - AmarinNASDAQ:AMRNStock Price: $0.88 (+$0.01)P/E Ratio: -6.29Market Cap: $361.39 millionAverage Trading Volume: 2.00 million sharesConsensus Rating: Reduce (1 Buy Ratings, 1 Hold Ratings, 2 Sell Ratings)Consensus Price Target: $1.08 (23.1% Upside)Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.#24 - CommScopeNASDAQ:COMMStock Price: $0.97 (-$0.05)P/E Ratio: -0.14Market Cap: $206.26 millionAverage Trading Volume: 2.89 million sharesConsensus Rating: Reduce (0 Buy Ratings, 5 Hold Ratings, 2 Sell Ratings)Consensus Price Target: $4.02 (313.7% Upside)CommScope Holding Company, Inc. provides infrastructure solutions for communications, data center, and entertainment networks worldwide. The company operates through Connectivity and Cable Solutions (CCS); Outdoor Wireless Networks (OWN); Networking, Intelligent Cellular and Security Solutions (NICS), and Access Network Solutions (ANS) segments. The CCS segment provides network solutions for indoor and outdoor network applications; and fiber optic and copper connectivity and cable solutions for use in telecommunications, cable television, residential broadband networks, data centers and business enterprises. The OWN segment provides base station antennas, radio frequency filters, tower connectivity, microwave antennas, metro cell products, cabinets, steel towers, accessories, wireless Spectrum management business and Comsearch products. The NICS segment offers indoor and outdoor Wi-Fi and long-term evolution (LTE) access points, access and aggregation switches; an Internet of Things suite, on-premises and cloud-based control and management systems; and software and software-as-a-service applications. The ANS segment offers cable modem termination systems, video infrastructure, distribution and transmission equipment and cloud solutions that enable facility-based service providers to construct a state-of-the-art residential and metro distribution network. It offers its products and services through independent distributors, specialized resellers and distributors, wireless and wireline operators, original equipment manufacturers, and system integrators, as well as directly to customers. The company was formerly known as Cedar I Holding Company, Inc. and changed its name to CommScope Holding Company, Inc. in January 2011. CommScope Holding Company, Inc. was founded in 1976 and is based in Claremont, North Carolina.#25 - FiskerNYSE:FSRStock Price: $0.09 (-$0.04)P/E Ratio: -0.04Market Cap: $31.45 millionAverage Trading Volume: 85.29 million sharesConsensus Rating: Reduce (1 Buy Ratings, 4 Hold Ratings, 4 Sell Ratings)Consensus Price Target: $2.76 (2,972.0% Upside)Fisker Inc. develops, manufactures, markets, leases, or sells electric vehicles. It operates through three segments: The White Space, The Value Segment, and The Conservative Premium segments. The company is also involved in asset-light automotive business. In addition, it offers fisker flexible platform agnostic design, a process that develops and designs electric vehicles in specific segment size. The company was incorporated in 2016 and is headquartered in Manhattan Beach, California. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Beyond the Halving: The Future of Bitcoin Mining Stocks Charles Schwab Fortifies its Uptrend on EPS Beat Extreme Networks Snags an Upgrade on Inventory Normalization MarketBeat Week in Review – 4/15 - 4/19 Salesforce Stock Analysis: Deep Dive into CRM Market Performance Taiwan Semiconductor Earnings: AI Dominance and Future Outlook CSX Co.: The Railroad Powering Ahead with an Earnings Beat D.R. Horton Stock Has Tailwinds To Drive it Higher Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
